Español
Questions About Cancer? 1-800-4-CANCER
  • Email

Clinical Trials Search Results

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
  •          
Help with display options.
Results 1-25 of 49 for your search:
Cancer Type/Condition:  Skin cancer, melanoma
Trial Type:  Treatment
Treatment/Intervention:  vaccine therapy
Trial Status:  Active
Start Over
        Show
1.

Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 18 to 65
Sponsor: Pharmaceutical / Industry
Protocol IDs: CASVAC0401, NCT01729663

2.

Phase: Phase III, Phase II
Type: Treatment
Status: Approved-not yet active
Age: Not specified
Sponsor: Other
Protocol IDs: 0419-12-HMO, NCT01861938

3.

Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: WIRB Protocol: 20141932, NCT02301611

4.

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: CL-CA-P01-00-US, 2014-000544-15, NCT01875653

5.

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 19 to 90
Sponsor: Other
Protocol IDs: SuMo-Sec-01, PEI 0899/01, IRB 07/03, NCT00108875

6.

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 to 65
Sponsor: Other
Protocol IDs: pepDCIL2- HMO-CTIL, NCT00279058

7.

Phase: Phase II, Phase I
Type: Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: Other
Protocol IDs: GCO 13-1391, NCT01079741

8.

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: SCIB1-001, NCT01138410

9.

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: Luc 10-002, NCT01191034

10.

Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Approved-not yet active
Age: 18 to 60
Sponsor: Other
Protocol IDs: 6889, CNPq 577582/2008-9, NCT01584115

11.

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: LUC 10-001, NCT01723813

12.

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 to 75
Sponsor: Pharmaceutical / Industry
Protocol IDs: NWBio 050012, NCT01882946

13.

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: Not specified
Sponsor: Other
Protocol IDs: 0419-12-HMO-CTIL, NCT01898039

14.

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: 140053, 14-C-0053, NCT02054104

15.

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 15931, MEL60, NCT02126579

16.

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: UV1/hTERT-MM, NCT02275416

17.

Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: Other
Protocol IDs: I214, NCT02285816

18.

Phase: Phase II
Type: Treatment
Status: Active
Age: Any age
Sponsor: NCI, Other
Protocol IDs: CDR0000369699, DFCI-03123, NCT00085397

19.

Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: CD-2007-01, NCT00610389

20.

Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: 10-001212, 08-02-020, NCT00910650

21.

Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 2008-0416, NCI-2011-02363, NCT00960752

22.

Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: PHS IRB 06-55, NCT00961376

23.

Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 11854, NCT01502293

24.

Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: MM1120, NCT01543464

25.

Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: DC-MEL, NCT01676779
1   
New Search